Molecular docking experiments were carried out on newly discovered acridine-derivative anti-butyrylcholinesterase inhibitors. The docking analysis showed that the suggested drugs had a weak to moderate effect on the target enzyme butyrylcholinesterase. The Protein Data Bank's accession number PDB:2XQF was utilized in docking studies. PyRx 0.9 was used to complete the docking process. Compounds 70 and 91 showed similar docking to donepezil (12.76 k/Cal), as did Compounds 40, 56, and 68 (11.1 k/Cal), Compounds 37, 48, and 72 (11.2 k/Cal), Compounds 39 and 47 (11.3 k/Cal), Compounds 38 and 67 (11.4 k/Cal), Compounds 55 and 69 (11.5 k/Cal), and Compound 69 (11.6 k/Cal). The remaining chemicals show moderate to good activity when compared to the standard treatment. The results of ADMET prediction also revealed that these medicines would be safer and more interesting in terms of their pharmacokinetic properties.